Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  recombinant interferon alfa-2b
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-19 of 19 for your search:
Start Over
Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PLRG-14, NCT02323659
Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: CASVAC0401, NCT01729663
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: MM-ADJ-5, NCT00226408
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02649, ECOG-E1609, CDR0000692568, E1609, U10CA180820, U10CA021115, NCT01274338
Randomized Phase III of PRRT Versus Interferon
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: IJBMNCASTOR, 2012-005545-20, NCT01860742
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2011-0073, NCI-2011-02768, NCT01409174
Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-107, NCT01943422
aDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 12-110, 5P01CA132714-05, NCT02151448
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 11-128, 5P01CA132714, NCT02432378
Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 16 to 75
Sponsor: Other
Protocol IDs: CDR0000543536, SINGAPORE-OC-GI-01-06, SINGAPORE-IRB-06-16-HEP, SINGAPORE-CTC0600327, SPRI-SINGAPORE-OC-GI-01-06, OC-GI-01-06, NCT00471484
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01932, CDR0000741878, ECOG-E3611, E3611, U10CA180820, U10CA021115, NCT01708941
A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AMN107A2301, NCT01782508
Multiple Antigen-Engineered DC Vaccine for Melanoma
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 09-021, 1P50CA121973-01A1, NCT01622933
A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GO29322, 2014-000812-33, NCT02174172
Pilot Study of IFN a2b for Melanoma Patients
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-067, NCT00871533
Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-a2b for Melanoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-063, NCT01608594
Interferon a for the Therapy of Minimal Residual Disease
Phase: No phase specified
Type: Treatment
Status: Active
Age: 1 to 60
Sponsor: Other
Protocol IDs: 2014-02, NCT02185261
IFN-DLI for Relapsed Acute Leukemia After Allo-SCT
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 09414, NCT02331706
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: UPCI 14-102, NCT02339324
Start Over